The HER2 amplicon in breast cancer: Topoisomerase IIA and beyond

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1836, Issue 1, 2013, Pages 146-157

  Jacot, William ^a,b   Fiche, Maryse ^b   Zaman, Khalil ^b   Wolfer, Anita ^b   Lamy, Pierre Jean ^a  

^a CENTRE VAL D AURELLE   (France)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Amplicon; Breast cancer; HER2

Indexed keywords

CHEMOKINE RECEPTOR CCR7; CYTOKERATIN 19; CYTOKERATIN 20; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GASTRIN; GROWTH FACTOR RECEPTOR BOUND PROTEIN 7; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR BINDING PROTEIN; RETINOIC ACID RECEPTOR ALPHA; SOMATOMEDIN BINDING PROTEIN 4; THYROID HORMONE RECEPTOR ALPHA; TOPOISOMERASE IIA; TUMOR PROTEIN; UNCLASSIFIED DRUG;

AMPLICON; BREAST CANCER; CANCER PROGNOSIS; CHEMOKINE RECEPTOR CCR7 GENE; COPY NUMBER VARIATION; CYTOKERATIN 19 GENE; CYTOKERATIN 20 GENE; EPIDERMAL GROWTH FACTOR RECEPTOR 2 GENE; GASTRIN GENE; GENE AMPLIFICATION; GENE DELETION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GROWTH FACTOR RECEPTOR BOUND PROTEIN 7 GENE; HUMAN; NONHUMAN; NUMERICAL CHROMOSOME ABERRATION; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR BINDING PROTEIN GENE; POLYSOMY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINOIC ACID RECEPTOR ALPHA GENE; REVIEW; SOMATOMEDIN BINDING PROTEIN 4 GENE; START DOMAIN CONTAINING 3 GENE; THYROID HORMONE RECEPTOR ALPHA GENE; TOPOISOMERASE IIA GENE; TUMOR GENE;

ANIMALS; ANTHRACYCLINES; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; GENE AMPLIFICATION; HUMANS; RECEPTOR, ERBB-2;

EID: 84877888766     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2013.04.004     Document Type: Review

References (176)

1. Smith I., et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007, 369(9555):29-36.
2. Joensuu H., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 2006, 354(8):809-820.
3. Baehner F.L., et al. Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. J. Clin. Oncol. 2010, 28(28):4300-4306.
4. Dabbs D.J., et al. High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study. J. Clin. Oncol. 2011, 29(32):4279-4285.
5. Bhargava R., Dabbs D.J. Oncotype DX test on unequivocally HER2-positive cases: potential for harm. J. Clin. Oncol. 2012, 30(5):570-571.
6. Bartlett A.I., et al. Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition. Am. J. Clin. Pathol. 2011, 136(2):266-274.
7. Susini T., et al. Preoperative assessment of HER-2/neu status in breast carcinoma: the role of quantitative real-time PCR on core-biopsy specimens. Gynecol. Oncol. 2010, 116(2):234-239.
8. Vranic S., et al. Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17. Cancer 2011, 117(1):48-53.
9. Lamy P.J., et al. Reliability and discriminant validity of HER2 gene quantification and chromosome 17 aneusomy analysis by real-time PCR in primary breast cancer. Int. J. Biol. Markers 2006, 21(1):20-29.
10. Mano M.S., et al. The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours. Cancer Treat. Rev. 2007, 33(1):64-77.
11. Brase J.C., et al. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Clin. Cancer Res. 2010, 16(8):2391-2401.
12. Arriola E., et al. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res. Treat. 2007, 106(2):181-189.
13. Di Leo A., et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin. Cancer Res. 2002, 8(5):1107-1116.
14. Knoop A.S., et al. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J. Clin. Oncol. 2005, 23(30):7483-7490.
15. Tanner M., et al. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J. Clin. Oncol. 2006, 24(16):2428-2436.
16. Ejlertsen B., et al. HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients. J. Clin. Oncol. 2010, 28(6):984-990.
17. O'Malley F.P., et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J. Natl. Cancer Inst. 2009, 101(9):644-650.
18. Villman K., et al. TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer. Acta Oncol. 2006, 45(5):590-596.
19. Cardoso F., et al. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Int. J. Oncol. 2004, 24(1):201-209.
20. Jarvinen T.A., et al. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am. J. Pathol. 2000, 156(3):839-847.
21. Konecny G.E., et al. Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer. Breast Cancer Res. Treat. 2010, 120(2):481-489.
22. Kauraniemi P., et al. Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer. Am. J. Pathol. 2003, 163(5):1979-1984.
23. Arriola E., et al. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab. Invest. 2008, 88(5):491-503.
24. Glynn R.W., Miller N., Kerin M.J. 17q12-21 - the pursuit of targeted therapy in breast cancer. Cancer Treat. Rev. 2010, 36(3):224-229.
25. Kauraniemi P., Kallioniemi A. Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. Endocr. Relat. Cancer 2006, 13(1):39-49.
26. Kauraniemi P., et al. New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. Cancer Res. 2001, 61(22):8235-8240.
27. Luoh S.W. Amplification and expression of genes from the 17q11 approximately q12 amplicon in breast cancer cells. Cancer Genet. Cytogenet. 2002, 136(1):43-47.
28. Lambros M.B., et al. PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study. Mod. Pathol. 2010, 23(10):1334-1345.
29. Lamy P.J., et al. Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers. Breast Cancer Res. 2011, 13(1):R15.
30. Ellsworth R.E., et al. Amplification of HER2 is a marker for global genomic instability. BMC Cancer 2008, 8:297.
31. Nielsen K.V., et al. Aberrations of ERBB2 and TOP2A genes in breast cancer. Mol. Oncol. 2010, 4(2):161-168.
32. Katoh M. MGC9753 gene, located within PPP1R1B-STARD3-ERBB2-GRB7 amplicon on human chromosome 17q12, encodes the seven-transmembrane receptor with extracellular six-cystein domain. Int. J. Oncol. 2003, 22(6):1369-1374.
33. Bieche I., et al. Two distinct amplified regions at 17q11-q21 involved in human primary breast cancer. Cancer Res. 1996, 56(17):3886-3890.
34. Sircoulomb F., et al. Genome profiling of ERBB2-amplified breast cancers. BMC Cancer 2010, 10:539.
35. Staaf J., et al. High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer. Breast Cancer Res. 2010, 12(3):R25.
36. Kwei K.A., et al. Genomic instability in breast cancer: pathogenesis and clinical implications. Mol. Oncol. 2010, 4(3):255-266.
37. Albertson D.G. Gene amplification in cancer. Trends Genet. 2006, 22(8):447-455.
38. Kao J., Pollack J.R. RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes. Genes Chromosomes Cancer 2006, 45(8):761-769.
39. Vinatzer U., et al. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization. Clin. Cancer Res. 2005, 11(23):8348-8357.
40. Alpy F., et al. Metastatic lymph node 64 (MLN64), a gene overexpressed in breast cancers, is regulated by Sp/KLF transcription factors. Oncogene 2003, 22(24):3770-3780.
41. Marchio C., et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J. Pathol. 2009, 219(1):16-24.
42. Bartlett J.M., et al. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol. 2010, 11(3):266-274.
43. Tse C.H., et al. Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy. J. Clin. Oncol. 2011, 29(31):4168-4174.
44. Kouvaras E., et al. Comparative study of spatial localization of HER-2 and CEP17 signals and of HER-2/CEP17 ratios, in "thin" and "thick" tissue sections. Breast 2012, 21(1):34-39.
45. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 1999, 57(7):727-741.
46. Binaschi M., et al. Anthracyclines: selected new developments. Curr. Med. Chem. Anticancer Agents 2001, 1(2):113-130.
47. Minotti G., et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004, 56(2):185-229.
48. Perego P., et al. Role of apoptosis and apoptosis-related genes in cellular response and antitumor efficacy of anthracyclines. Curr. Med. Chem. 2001, 8(1):31-37.
49. Lage H., et al. Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance. Br. J. Cancer 2000, 82(2):488-491.
50. Paik S., et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J. Natl. Cancer Inst. 1998, 90(18):1361-1370.
51. Pritchard K.I., et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N. Engl. J. Med. 2006, 354(20):2103-2111.
52. Gennari A., Pronzato P. New understanding of the role of anthracyclines in early-stage breast cancer: patient selection considerations. Clin. Breast Cancer 2008, 8(Suppl. 4):S179-S183.
53. Du Y., et al. The role of topoisomerase IIalpha in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures. Breast Cancer Res. Treat. 2011, 129(3):839-848.
54. Di Leo A., et al. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol. 2011, 12(12):1134-1142.
55. Wang J., et al. TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy. Breast Cancer Res. Treat. 2012, 135(2):531-537.
56. Slamon D., et al. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 2011, 365(14):1273-1283.
57. Fountzilas G., et al. HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. J. Transl. Med. 2012, 10:10.
58. Pierceall W.E., et al. Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer. Hum. Pathol. 2012, 43(9):1363-1375.
59. Press M.F., et al. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J. Clin. Oncol. 2011, 29(7):859-867.
60. Harris L.N., et al. Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. J. Clin. Oncol. 2009, 27(21):3430-3436.
61. Tubbs R., et al. Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. J. Clin. Oncol. 2009, 27(24):3881-3886.
62. Glynn R.W., et al. TOP2A amplification in the absence of that of HER-2/neu: toward individualization of chemotherapeutic practice in breast cancer. Oncologist 2011, 16(7):949-955.
63. Lamy P.J., Jacot W. TOP2A Amplification in Breast Cancer in the Absence of that of HER-2: Myth or Reality?. Oncologist 2012, 17(12):e60-1.
64. Bartlett J.M., et al. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol. 2011, 11(3):266-274.
65. Hicks D.G., et al. The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study. Hum. Pathol. 2005, 36(4):348-356.
66. Chibon F., et al. Prediction of HER2 gene status in Her2 2+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations. Mod. Pathol. 2009, 22(3):403-409.
67. Wolff A.C., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007, 25(1):118-145.
68. Vance G.H., et al. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch. Pathol. Lab. Med. 2009, 133(4):611-612.
69. Ohlschlegel C., et al. HER2 genetic heterogeneity in breast carcinoma. J. Clin. Pathol. 2011, 64(12):1112-1116.
70. Starczynski J., et al. HER2 gene amplification in breast cancer: a rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations. Am. J. Clin. Pathol. 2012, 137(4):595-605.
71. Dal Lago L., et al. Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. Mol. Cancer Ther. 2006, 5(10):2572-2579.
72. Varga Z., et al. Topoisomerase 2A gene amplification in breast cancer. Critical evaluation of different FISH probes. Breast Cancer Res. Treat. 2011, 133(3):929-935.
73. D'Haene B., Vandesompele J., Hellemans J. Accurate and objective copy number profiling using real-time quantitative PCR. Methods 2010, 50(4):262-270.
74. Zaczek A., et al. Clinical evaluation of developed PCR-based method with hydrolysis probes for TOP2A copy number evaluation in breast cancer samples. Clin. Biochem. 2010, 43(10-11):891-898.
75. Zaczek A.J., et al. Prognostic significance of TOP2A gene dosage in HER-2-Negative breast cancer. Oncologist 2012, 17(10):1246-1255.
76. Durbecq V., et al. Correlation between topoisomerase-IIalpha gene amplification and protein expression in HER-2 amplified breast cancer. Int. J. Oncol. 2004, 25(5):1473-1479.
77. Mueller R.E., et al. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chromosomes Cancer 2004, 39(4):288-297.
78. Callagy G., et al. Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays. J. Pathol. 2005, 205(3):388-396.
79. Isaacs R.J., et al. Physiological regulation of eukaryotic topoisomerase II. Biochim. Biophys. Acta 1998, 1400(1-3):121-137.
80. Goswami P.C., et al. Cell cycle-coupled variation in topoisomerase IIalpha mRNA is regulated by the 3'-untranslated region. Possible role of redox-sensitive protein binding in mRNA accumulation. J. Biol. Chem. 2000, 275(49):38384-38392.
81. Jarvinen T.A., et al. Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. Am. J. Pathol. 1996, 148(6):2073-2082.
82. Romero A., et al. Assessment of Topoisomerase II alpha status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization. Am. J. Pathol. 2011, 178(4):1453-1460.
83. Srikantan S., et al. Translational control of TOP2A influences doxorubicin efficacy. Mol. Cell. Biol. 2011, 31(18):3790-3801.
84. Mo Y.Y., Beck W.T. Heterogeneous expression of DNA topoisomerase II alpha isoforms in tumor cell lines. Oncol. Res. 1997, 9(4):193-204.
85. Meng H., et al. Correlations of TOP2A gene aberrations and expression of topoisomerase IIalpha protein and TOP2A mRNA expression in primary breast cancer: a retrospective study of 86 cases using fluorescence in situ hybridization and immunohistochemistry. Pathol. Int. 2012, 62(6):391-399.
86. Brandeis M., Hunt T. The proteolysis of mitotic cyclins in mammalian cells persists from the end of mitosis until the onset of S phase. EMBO J. 1996, 15(19):5280-5289.
87. Oakman C., et al. The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients. Cancer Treat. Rev. 2009, 35(8):662-667.
88. Pritchard K.I., et al. HER-2 and topoisomerase II as predictors of response to chemotherapy. J. Clin. Oncol. 2008, 26(5):736-744.
89. Slamon D.J., Press M.F. Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers. J. Natl. Cancer Inst. 2009, 101(9):615-618.
90. Jarvinen T.A., et al. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 1999, 26(2):142-150.
91. Bofin A.M., Ytterhus B., Hagmar B.M. TOP2A and HER-2 gene amplification in fine needle aspirates from breast carcinomas. Cytopathology 2003, 14(6):314-319.
92. Di Leo A., et al. Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime?. Eur. J. Cancer 2008, 44(18):2791-2798.
93. Corzo C., et al. Does polysomy of chromosome 17 have a role in ERBB2 and topoisomerase IIalpha expression? Gene, mRNA and protein expression: a comprehensive analysis. Tumour Biol. 2007, 28(4):221-228.
94. Zhu Y., et al. Isolation and characterization of PBP, a protein that interacts with peroxisome proliferator-activated receptor. J. Biol. Chem. 1997, 272(41):25500-25506.
95. Zhang D., et al. Arginine and glutamate-rich 1 (ARGLU1) interacts with mediator subunit 1 (MED1) and is required for estrogen receptor-mediated gene transcription and breast cancer cell growth. J. Biol. Chem. 2011, 286(20):17746-17754.
96. Warnmark A., et al. Differential recruitment of the mammalian mediator subunit TRAP220 by estrogen receptors ERalpha and ERbeta. J. Biol. Chem. 2001, 276(26):23397-23404.
97. Wu Q., Burghardt R., Safe S. Vitamin D-interacting protein 205 (DRIP205) coactivation of estrogen receptor alpha (ERalpha) involves multiple domains of both proteins. J. Biol. Chem. 2004, 279(51):53602-53612.
98. Burakov D., et al. Functional interactions between the estrogen receptor and DRIP205, a subunit of the heteromeric DRIP coactivator complex. J. Biol. Chem. 2000, 275(27):20928-20934.
99. Kang Y.K., et al. The TRAP/Mediator coactivator complex interacts directly with estrogen receptors alpha and beta through the TRAP220 subunit and directly enhances estrogen receptor function in vitro. Proc. Natl. Acad. Sci. U. S. A. 2002, 99(5):2642-2647.
100. Jiang P., et al. Key roles for MED1 LxxLL motifs in pubertal mammary gland development and luminal-cell differentiation. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(15):6765-6770.
101. Acevedo M.L., et al. Selective recognition of distinct classes of coactivators by a ligand-inducible activation domain. Mol. Cell 2004, 13(5):725-738.
102. Zhang X., et al. MED1/TRAP220 exists predominantly in a TRAP/ Mediator subpopulation enriched in RNA polymerase II and is required for ER-mediated transcription. Mol. Cell 2005, 19(1):89-100.
103. Nagalingam A., et al. Med1 plays a critical role in the development of tamoxifen resistance. Carcinogenesis 2012, 33(4):918-930.
104. Zhu Y., et al. Amplification and overexpression of peroxisome proliferator-activated receptor binding protein (PBP/PPARBP) gene in breast cancer. Proc. Natl. Acad. Sci. U. S. A. 1999, 96(19):10848-10853.
105. Miller L.D., et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(38):13550-13555.
106. Ivshina A.V., et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 2006, 66(21):10292-10301.
107. Moog-Lutz C., et al. MLN64 exhibits homology with the steroidogenic acute regulatory protein (STAR) and is over-expressed in human breast carcinomas. Int. J. Cancer 1997, 71(2):183-191.
108. Strauss J.F., et al. START domain proteins and the intracellular trafficking of cholesterol in steroidogenic cells. Mol. Cell. Endocrinol. 2003, 202(1-2):59-65.
109. Dressman M.A., et al. Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer. Cancer Res. 2003, 63(9):2194-2199.
110. Tomasetto C., et al. Identification of four novel human genes amplified and overexpressed in breast carcinoma and localized to the q11-q21.3 region of chromosome 17. Genomics 1995, 28(3):367-376.
111. Cai W., et al. Expression of MLN64 influences cellular matrix adhesion of breast cancer cells, the role for focal adhesion kinase. Int. J. Mol. Med. 2010, 25(4):573-580.
112. Akiyama N., et al. Isolation of a candidate gene, CAB1, for cholesterol transport to mitochondria from the c-ERBB-2 amplicon by a modified cDNA selection method. Cancer Res. 1997, 57(16):3548-3553.
113. Alpy F., et al. The steroidogenic acute regulatory protein homolog MLN64, a late endosomal cholesterol-binding protein. J. Biol. Chem. 2001, 276(6):4261-4269.
114. Stein D., et al. The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. EMBO J. 1994, 13(6):1331-1340.
115. Pero S.C., et al. Identification of novel non-phosphorylated ligands, which bind selectively to the SH2 domain of Grb7. J. Biol. Chem. 2002, 277(14):11918-11926.
116. Han D.C., Shen T.L., Guan J.L. The Grb7 family proteins: structure, interactions with other signaling molecules and potential cellular functions. Oncogene 2001, 20(44):6315-6321.
117. Daly R.J. The Grb7 family of signalling proteins. Cell. Signal. 1998, 10(9):613-618.
118. Saito M., et al. Expression screening of 17q12-21 amplicon reveals GRB7 as an ERBB2-dependent oncogene. FEBS Lett. 2012, 586(12):1708-1714.
119. Shen T.L., Guan J.L. Differential regulation of cell migration and cell cycle progression by FAK complexes with Src, PI3K, Grb7 and Grb2 in focal contacts. FEBS Lett. 2001, 499(1-2):176-181.
120. van Agthoven T., et al. Functional identification of genes causing estrogen independence of human breast cancer cells. Breast Cancer Res. Treat. 2009, 114(1):23-30.
121. Nadler Y., et al. Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer. Ann. Oncol. 2010, 21(3):466-473.
122. Ramsey B., et al. GRB7 protein over-expression and clinical outcome in breast cancer. Breast Cancer Res. Treat. 2011, 127(3):659-669.
123. Paik S., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 2004, 351(27):2817-2826.
124. Cristofanilli M., et al. Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer 2005, 103(6):1122-1128.
125. van de Vijver M., et al. Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol. Cell. Biol. 1987, 7(5):2019-2023.
126. Futreal P.A., et al. Detection of frequent allelic loss on proximal chromosome 17q in sporadic breast carcinoma using microsatellite length polymorphisms. Cancer Res. 1992, 52(9):2624-2627.
127. Giovanella L., et al. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA). Clin. Chem. Lab. Med. 2002, 40(3):298-303.
128. Yokota J., et al. Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene 1988, 2(3):283-287.
129. Wang C.S., Lin K.H., Hsu Y.C. Alterations of thyroid hormone receptor alpha gene: frequency and association with Nm23 protein expression and metastasis in gastric cancer. Cancer Lett. 2002, 175(2):121-127.
130. Nakata B., et al. Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer. Br. J. Cancer 2004, 91(5):873-878.
131. Conde I., et al. Influence of thyroid hormone receptors on breast cancer cell proliferation. Ann. Oncol. 2006, 17(1):60-64.
132. Bidard F.C., et al. Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study. Breast Cancer Res. 2012, 14(1):R29.
133. Stathopoulos E.N., et al. Detection of CK-19 mRNA-positive cells in the peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes. Ann. Oncol. 2005, 16(2):240-246.
134. Ross-Innes C.S., et al. Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer. Genes Dev. 2010, 24(2):171-182.
135. Choi I., Gudas L.J., Katzenellenbogen B.S. Regulation of keratin 19 gene expression by estrogen in human breast cancer cells and identification of the estrogen responsive gene region. Mol. Cell. Endocrinol. 2000, 164(1-2):225-237.
136. Keith W.N., et al. Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20. Eur. J. Cancer 1993, 29A(10):1469-1475.
137. Tari A.M., et al. Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells. Oncogene 2002, 21(34):5224-5232.
138. Paroni G., et al. Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA. Oncogene 2012, 31(29):3431-3443.
139. Afonja O., et al. Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis. Oncogene 2004, 23(49):8135-8145.
140. Inoue A., et al. Development of cDNA microarray for expression profiling of estrogen-responsive genes. J. Mol. Endocrinol. 2002, 29(2):175-192.
141. Frasor J., et al. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 2003, 144(10):4562-4574.
142. Mita K., et al. Prognostic significance of insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5 expression in breast cancer. Jpn. J. Clin. Oncol. 2007, 37(8):575-582.
143. Sachdev D., Yee D. The IGF system and breast cancer. Endocr. Relat. Cancer 2001, 8(3):197-209.
144. Neely E.K., Rosenfeld R.G. Insulin-like growth factors (IGFs) reduce IGF-binding protein-4 (IGFBP-4) concentration and stimulate IGFBP-3 independently of IGF receptors in human fibroblasts and epidermal cells. Endocrinology 1992, 130(2):985-993.
145. Figueroa J.A., et al. Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status. J. Cell. Biochem. 1993, 52(2):196-205.
146. McGuire S.E., et al. Detection of insulin-like growth factor binding proteins (IGFBPs) by ligand blotting in breast cancer tissues. Cancer Lett. 1994, 77(1):25-32.
147. Yoshida N., et al. Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes. Cancer Sci. 2004, 95(6):496-502.
148. Vendrell J.A., et al. A candidate molecular signature associated with tamoxifen failure in primary breast cancer. Breast Cancer Res. 2008, 10(5):R88.
149. Liu Y., et al. Correlation effect of EGFR and CXCR4 and CCR7 chemokine receptors in predicting breast cancer metastasis and prognosis. J. Exp. Clin. Cancer Res. 2010, 29:16.
150. Steinman R.M., Pack M., Inaba K. Dendritic cells in the T-cell areas of lymphoid organs. Immunol. Rev. 1997, 156:25-37.
151. Forster R., Davalos-Misslitz A.C., Rot A. CCR7 and its ligands: balancing immunity and tolerance. Nat. Rev. Immunol. 2008, 8(5):362-371.
152. Muller A., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410(6824):50-56.
153. Cunningham H.D., et al. Expression of the C-C chemokine receptor 7 mediates metastasis of breast cancer to the lymph nodes in mice. Transl. Oncol. 2010, 3(6):354-361.
154. Kim S.J., et al. MicroRNA let-7a suppresses breast cancer cell migration and invasion through downregulation of C-C chemokine receptor type 7. Breast Cancer Res. 2012, 14(1):R14.
155. Cabioglu N., et al. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin. Cancer Res. 2005, 11(16):5686-5693.
156. Cabioglu N., et al. Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications. Ann. Oncol. 2009, 20(6):1013-1019.
157. Andre F., et al. Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann. Oncol. 2006, 17(6):945-951.
158. Cabioglu N., et al. Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Ann. Oncol. 2007, 18(6):1021-1029.
159. Coulombe P.A., Omary M.B. 'Hard' and 'soft' principles defining the structure, function and regulation of keratin intermediate filaments. Curr. Opin. Cell Biol. 2002, 14(1):110-122.
160. Karantza V. Keratins in health and cancer: more than mere epithelial cell markers. Oncogene 2011, 30(2):127-138.
161. Zhang D.H., et al. Proteomics of breast cancer: enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors. Proteomics 2005, 5(7):1797-1805.
162. Nakata B., et al. Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma. Cancer 2000, 89(6):1285-1290.
163. Alix-Panabieres C., et al. Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. Breast Cancer Res. 2009, 11(3):R39.
164. Ignatiadis M., et al. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin. Cancer Res. 2008, 14(9):2593-2600.
165. Pierga J.Y., et al. Prognostic value of cytokeratin 19 fragment (CYFRA 21-1) and cytokeratin-positive cells in bone marrow samples of breast cancer patients. Int. J. Biol. Markers 2004, 19(1):23-31.
166. Bambang I.F., et al. Cytokeratin 19 regulates endoplasmic reticulum stress and inhibits ERp29 expression via p38 MAPK/XBP-1 signaling in breast cancer cells. Exp. Cell Res. 2009, 315(11):1964-1974.
167. Moll R., et al. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am. J. Pathol. 1992, 140(2):427-447.
168. Tunca B., et al. CK19, CK20, EGFR and HER2 status of circulating tumor cells in patients with breast cancer. Tumori 2012, 98(2):243-251.
169. Cheng C.W., et al. The clinical implications of MMP-11 and CK-20 expression in human breast cancer. Clin. Chim. Acta 2010, 411(3-4):234-241.
170. Wang S.M., et al. Association of CK20 expression with the progression, metastasis and prognosis of breast cancer. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2009, 25(8):706-707.
171. Calatayud S., Alvarez A., Victor V.M. Gastrin: an acid-releasing, proliferative and immunomodulatory peptide?. Mini Rev. Med. Chem. 2010, 10(1):8-19.
172. Vidgren V., et al. Concomitant gastrin and ERBB2 gene amplifications at 17q12-q21 in the intestinal type of gastric cancer. Genes Chromosomes Cancer 1999, 24(1):24-29.
173. Grabowska A.M., Watson S.A. Role of gastrin peptides in carcinogenesis. Cancer Lett. 2007, 257(1):1-15.
174. Ferrand A., Wang T.C. Gastrin and cancer: a review. Cancer Lett. 2006, 238(1):15-29.
175. Goettler D.M., Levin L., Chey W.Y. Postprandial levels of prolactin and gut hormones in breast cancer patients: association with stage of disease, but not dietary fat. J. Natl. Cancer Inst. 1990, 82(1):22-29.
176. Nesland J.M., et al. Neurone specific enolase immunostaining in the diagnosis of breast carcinomas with neuroendocrine differentiation. Its usefulness and limitations. J. Pathol. 1986, 148(1):35-43.